SBIR-STTR Award

Nuclear Matrix Proteins CC 4/CC-5--Colon Cancer Markers
Award last edited on: 3/6/19

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$99,358
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Susan Keesee

Company Information

MZT Holdings Inc (AKA: Matritech Inc)

330 Nevada Street
Newton, MA 02460
   (617) 928-0820
   schubb@matritech.com
   www.matritech.com
Location: Multiple
Congr. District: 04
County: Middlesex

Phase I

Contract Number: 1R43CA067643-01
Start Date: 3/24/95    Completed: 9/24/95
Phase I year
1995
Phase I Amount
$99,358
Two putative colon cancer markers, CC-4 and CC-5, have been identified in colon cancers but not normal colon by Matritech scientists. MAbs specific for these proteins have been selected by immunofluorescent nuclear antigen localization on the CC- 4/CC-5-positive tumor cell line DLD and immunoblots against DLD-extracted nuclear matrix proteins. Following further characterization of CC-4-- and CC- 5-specific antibodies by two- dimensional immunoblotting on nuclear matrix proteins extracted from colon cancer tissue, selected antibodies will be tested for tissue specificity by immunohistochemical localization of CC-4 or CC-5 antigens in stool or serum from colorectal cancer patients by Western blot and enzyme immunoassay. Immunohistochemical methods will be used to search for these antigens in paraffin embedded colon tumor and polyp tissue. If tissue localization can distinguish cancer patients from normal controls, or if CC-4 or CC-5 can be detected in stool or serum, then immunoassays based upon the detection of these proteins could improve patient management or aid in the early detection of colon cancer National Cancer Institute (NCI).

Project Terms:
adenomatous polyps; antitumor antibody; colon neoplasms; feces; human tissue; immunocytochemistry; immunologic assay /test; monoclonal antibody; neoplasm /cancer diagnosis; nuclear matrix; serum; tumor antigens; western blottings

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----